Pacific Edge Wins Medicare Coverage for Cxbladder Triage

Pacific Edge (ASX:PEB) announced that the final Medicare Local Coverage Determination (LCD) for urine-based biomarkers in microhematuria patients has been published, confirming Medicare coverage for its Cxbladder Triage and Triage Plus tests.

The final LCD, L40378, establishes hematuria evaluation as a covered Medicare benefit for intermediate risk microhematuria patients and is scheduled to become effective on 20 December 2026. Pacific Edge says only Cxbladder Triage and Triage Plus are covered by the final LCD, with competing tests and generic billing codes non-covered. Management estimates about 1.14 million testing opportunities per year in that patient group. Triage and Monitor were recently re-priced under PAMA at US$1057/test and US$1026/test, and Triage Plus is priced at US$1,328/test. The company says the final LCD substantially resembles the draft published in May 2026, and its focus remains migrating hematuria testing to Triage Plus and improving average selling price through commercial payers. Commercially contracted lives for its hematuria tests total 12.9 million, in addition to Medicare, which covers more than 71 million lives. Pacific Edge is making selective investments in its commercial team and digital technologies.

The release gives no revenue or test volume forecast. Reliable Medicare Advantage reimbursement and wider commercial payer adoption are company expectations, not confirmed outcomes.